✦ LIBER ✦

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

✍ Scribed by Fiore, F Di; Charbonnier, F; Lefebure, B; Laurent, M; Pessot, F Le; Michel, P; Frebourg, T

Book ID: 109999545
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 75 KB
Volume: 99
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6604451

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

BRAF mutation predicts resistance to ant

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer

✍ Chen Mao; Ru-Yan Liao; Qing Chen 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 118 KB

Clinical relevance of KRAS mutation dete

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

✍ Di Fiore, F; Blanchard, F; Charbonnier, F; Le Pessot, F; Lamy, A; Galais, M P; B 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

KRAS mutation status in colorectal cance

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

✍ Rouleau, E; Spyratos, F; Dieumegard, B; Guinebretière, J M; Lidereau, R; Bièche, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 50 KB

Immunoglobulin G fragment C receptor pol

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

✍ David Paez; Laia Paré; Iñigo Espinosa; Juliana Salazar; Elisabeth Del Rio; Agust 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

Additional value of EGFR downstream sign

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer

✍ Geraldine Perkins; Astrid Lièvre; Carole Ramacci; Tchao Méatchi; Aurélien de Rey 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 393 KB

## Abstract __KRAS__ mutations are a strong predictive marker of resistance to anti‐epidermal growth factor receptor (EGFR) antibodies in advanced colorectal cancer (CRC) but only a subset of wild‐type (WT) __KRAS__ patients are responders, suggesting the existence of additional markers of resistan

A novel high-resolution chipCE assay for

A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA

✍ Marek Minarik; Marcus Gassman; Barbora Belsanova; Milos Pesek; Jan Schouten; Ric 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

There is a growing interest in evaluating molecular markers as predictors of response to new generation of targeted cancer therapies. One of such areas is biological therapy targeting epidermal growth factor receptor gene (EGFR) in lung cancer. The testing of tumor tissue is focused on specific EGFR